📧 FREE CASE EVALUATION: info@glp1lawsuits.com
← Back to Home

Gastrointestinal Side Effects

Comprehensive information about the serious gastrointestinal complications associated with GLP-1 medications, including gastroparesis, bowel obstruction, and intestinal tissue death.

Gastrointestinal Complications Overview

⚠️ Serious GI Complications Warning

GLP-1 medications have been linked to severe gastrointestinal complications that can be life-threatening. If you experience persistent nausea, vomiting, severe abdominal pain, or inability to eat, seek immediate medical attention.

How GLP-1 Drugs Affect the Digestive System

GLP-1 receptor agonists like Ozempic and Wegovy work by slowing down gastric emptying - the process by which food moves from the stomach to the small intestine. While this effect helps with weight loss by creating feelings of fullness, it can also lead to serious complications:

  • Delayed Gastric Emptying: Food stays in the stomach longer than normal
  • Reduced Intestinal Motility: Slower movement of food through the intestines
  • Altered Digestive Hormones: Changes in how the body processes food
  • Inflammation: Potential inflammatory effects on digestive organs
24,499
Emergency Visits
70%
Report Nausea
30%
Experience Vomiting
25%
Have Constipation

Gastroparesis (Stomach Paralysis)

What is Gastroparesis?

Gastroparesis is a condition where the stomach cannot empty properly due to nerve damage or muscle dysfunction. In the context of GLP-1 medications, this occurs because the drugs intentionally slow gastric emptying, but in some cases, this effect becomes permanent or severe.

Common Symptoms:
  • Severe nausea and vomiting
  • Feeling full after eating small amounts
  • Abdominal pain and bloating
  • Acid reflux and heartburn
  • Loss of appetite
  • Weight loss due to inability to eat

Gastroparesis Details

A condition where the stomach cannot empty properly, leading to severe nausea, vomiting, and abdominal pain. Many patients require surgical intervention.

Click for detailed information →

Treatment Options

Treatment may include dietary changes, medications to stimulate stomach emptying, or in severe cases, surgical procedures like gastric pacemakers or feeding tubes.

Research Findings

A study published in JAMA in October 2023 found that people taking GLP-1 drugs had a significantly higher risk of gastroparesis compared to those taking other weight loss medications. The study analyzed data from over 5,000 patients and found a 3.67-fold increased risk.

Bowel Obstruction

Understanding Bowel Obstruction

Bowel obstruction occurs when there is a blockage preventing food or liquid from moving through the intestines. This can be a life-threatening emergency requiring immediate medical intervention.

Warning Signs:
  • Severe abdominal pain and cramping
  • Inability to pass gas or have bowel movements
  • Nausea and vomiting
  • Abdominal swelling and bloating
  • Loss of appetite
  • Fever (indicating infection)

Bowel Obstruction Details

Blockages preventing food or liquid from moving through the intestines, requiring emergency medical intervention.

Click for detailed information →

Emergency Treatment

Bowel obstruction is a medical emergency that may require hospitalization, IV fluids, and sometimes surgery to remove the blockage.

⚠️ Emergency Warning

If you experience symptoms of bowel obstruction, seek immediate medical attention. This condition can be life-threatening if not treated promptly.

Intestinal Tissue Death

Intestinal Tissue Death (Necrosis)

In severe cases, GLP-1 medications have been linked to intestinal tissue death, where parts of the intestine lose blood supply and die. This is an extremely serious complication that requires immediate surgical intervention.

Critical Symptoms:
  • Severe, sudden abdominal pain
  • Abdominal tenderness and rigidity
  • Fever and chills
  • Rapid heart rate
  • Low blood pressure
  • Signs of shock

Intestinal Tissue Death Details

As reported in multiple cases, requiring surgical removal and permanent ileostomy. Some patients have lost parts of their large intestine.

Click for detailed information →

Surgical Consequences

Patients may require removal of dead intestinal tissue, leading to permanent ileostomy bags and significant lifestyle changes.

Notable Case: Juanita Gantt

A 62-year-old patient was hospitalized after taking Wegovy and Ozempic. Parts of her large intestine died and needed to be removed. She now lives with a permanent ileostomy bag and has filed a lawsuit against the manufacturers.

Pancreatitis

Inflammation of the Pancreas

Pancreatitis is inflammation of the pancreas that can be life-threatening. Studies have shown an increased risk of pancreatitis in patients taking GLP-1 medications compared to other weight loss medications.

Pancreatitis Symptoms:
  • Severe upper abdominal pain that radiates to the back
  • Nausea and vomiting
  • Fever and rapid pulse
  • Abdominal tenderness
  • Jaundice (yellowing of skin and eyes)
  • Shock in severe cases

Pancreatitis Details

Inflammation of the pancreas that can be life-threatening. Studies show increased risk compared to other weight loss medications.

Click for detailed information →

Treatment and Recovery

Treatment typically involves hospitalization, IV fluids, pain management, and sometimes surgery. Recovery can take weeks to months.

Research Evidence

The JAMA study from October 2023 found that GLP-1 users had a 9.09-fold increased risk of pancreatitis compared to users of other weight loss medications. This represents a significant safety concern.

Research and Studies

Key Research Findings

Multiple studies have documented the serious gastrointestinal risks associated with GLP-1 medications:

October 2023

JAMA Study

Research published in JAMA found that people taking GLP-1 drugs had higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to other weight loss medications.

April 2025

Emergency Department Study

Study revealed that an estimated 24,499 people visited emergency departments for adverse events related to semaglutide in just two years following its approval.

May 2025

Poison Control Data

Pennsylvania and New Jersey poison control centers reported a steep rise in calls related to GLP-1 weight-loss drugs, with exposures jumping from 29 cases in 2021 to 189 in 2024.

FDA Monitoring

The FDA continues to monitor adverse event reports and has issued several warnings about GLP-1 medications. The agency has received thousands of reports of serious gastrointestinal complications, including:

  • Gastroparesis: Over 1,000 reports of stomach paralysis
  • Bowel Obstruction: Hundreds of cases requiring emergency surgery
  • Pancreatitis: Multiple reports of life-threatening inflammation
  • Intestinal Death: Cases requiring surgical removal of dead tissue